Paragraph 8 Prior approval procedure for major variations of type IIF1

(1)

The holder must submit to the licensing authority an application containing the elements listed in paragraph 9, and if the application contains those elements, the licensing authority must acknowledge receipt of a valid application.

(2)

Subject to sub-paragraph (3), within 60 days beginning with the date on which the licensing authority acknowledges receipt of a valid application under sub-paragraph (1), the licensing authority must conclude the assessment.

(3)

The licensing authority may—

(a)

reduce the period referred to in sub-paragraph (2), having regard to the urgency of the matter; or

(b)

extend it to 90 days for—

(i)

variations concerning a change to, or addition of, therapeutic indications, or

(ii)

grouping of variations in accordance with paragraph 5(2)(c).

(4)

Within the periods referred to in sub-paragraph (2) or (3), the licensing authority may request the holder to provide supplementary information within a time limit that it specifies, in which case—

(a)

the procedure is suspended from the date on which such a request is made until the date on which that supplementary information has been provided; and

(b)

the licensing authority may extend the period referred to in sub-paragraph (2) by the period for which the procedure is so suspended.

(5)

Within 30 days beginning with the date on which the licensing authority concludes its assessment of the application, the measures provided for in paragraph 10 are to be taken.

(6)

This paragraph does not apply where a type II variation request is submitted in a grouping that includes an extension: in such case, the procedure in paragraph 11 applies.

Annotations

Textual amendments

F1: Sch. 10A inserted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), reg. 1, Sch. 5; 2020 c. 1, Sch. 5 para. 1(1)